Jenny and Gemma Saddle up to Support Prostate Cancer UK as Randox Backs Charity at Iconic Grand National Festival
Jenny and Gemma Saddle up to Support Prostate Cancer UK as Randox Backs Charity at Iconic Grand National Festival
Sports News Release
Jenny and Gemma saddle up to support Prostate Cancer UK as Randox backs charity at iconic Grand National Festival
- Grand National headline sponsor Randox to donate sponsorship rights, including Ladies Day Race title, to help save men’s lives
- Leading men’s health charity to raise awareness of England’s most common cancer across iconic Festival
- Prostate Cancer UK supporters and broadcasters Jenny Powell and Gemma Oaten among Ladies Day special guests
Prostate Cancer UK will deliver life-saving messaging to thousands of racegoers at this year’s Grand National Festival thanks to headline sponsors, Randox.
Randox is donating the sponsorship of the title race to Prostate Cancer UK on Ladies Day on Friday April 4th, and broadcasters and special guests Jenny Powell and Gemma Oaten will be visiting the famous Festival, continuing their support for the leading men’s health charity.
Powell and Oaten will be in the stands to watch the Randox Supporting Prostate Cancer UK Topham Chase, with the Aintree event holding added significance for the duo, whose families have both been affected by prostate cancer. Jenny’s father died of prostate cancer in 2021, while Gemma’s dad, Dennis, is living with advanced prostate cancer.
Jenny Powell, who presents the weekend breakfast show on Greatest Hits Radio, said:
“Losing my dad to prostate cancer was heartbreaking, so I want to use my family’s experience to help others and continue the conversation about the disease.
“My dad was a strong, proud man who never liked talking about his health. His experience taught me that we need to encourage men to have open conversations about prostate cancer risk. That’s why it’s fantastic that Randox has picked Prostate Cancer UK as a charity partner of the Randox Grand National Festival.
“There will be a lot of men watching the racing at Aintree, and one in eight of them will get prostate cancer. That’s a scary statistic, but one that Prostate Cancer UK are working to reverse, and I’m delighted to be supporting the charity on Ladies Day this year.”
Former Emmerdale actress Oaten said:
“My dad is a massive horseracing fan, so being at the Randox Grand National on Ladies Day, supporting Prostate Cancer UK, is really exciting.
“When my dad was diagnosed with Stage 3 prostate cancer, our whole world stopped. Thankfully he’s still going strong today, and sharing his story has hopefully encouraged men like him to go to speak to their GP if they have any concerns themselves.
“Dad’s experience has also allowed me to work closely with Prostate Cancer UK and learn what fantastic work they do; not only in research into the disease, but supporting men and their families living with a diagnosis.
“It’ll be a real honour to represent the charity on Ladies Day, and I can’t wait to see the action at Aintree.”
Laura Kerby, Chief Executive of Prostate Cancer UK, said:
“We’re incredibly grateful to Randox for their generous support, and for providing such a significant platform to shine a spotlight on prostate cancer, the most common cancer in men.
“The Randox Grand National is one of the most iconic sporting events in the world, with the eyes of millions of horseracing fans across the UK firmly fixed on the action at Aintree every year. This partnership will enable Prostate Cancer UK to reach even more men with our lifesaving message and help save lives.”
Dr. Peter FitzGerald, Managing Director of Randox Health, said:
“At Randox, we are committed to improving health outcomes through innovation and early diagnosis, and we are honoured to support Prostate Cancer UK through our Grand National sponsorship. By dedicating the Ladies Day race to this important cause, we hope to drive greater awareness and encourage men to take charge of their health.
“Prostate cancer is the most common cancer in men, with risk increasing due to factors such as age, family history, and ethnicity. Early detection is crucial, as the disease often develops without symptoms in its early stages. By raising awareness of these risk factors and the importance of regular health checks, we aim to empower men with the knowledge they need to take proactive steps in safeguarding their health.”
The 2025 Randox Grand National Festival takes place from Thursday, April 3rd to Saturday, April 5th at Aintree Racecourse. The Randox Supporting Prostate Cancer UK Topham Chase will be held on Ladies Day, Friday April 4th, as runners and riders take on the iconic Grand National fences.
For more information on the Randox Grand National and Prostate Cancer UK, visit www.randox.com and www.prostatecanceruk.org.
Be Race Ready: Feel your best with Randox Health
Be Race Ready: Feel your best with Randox Health
Race day at the Randox Grand National isn’t just about the horses—it’s about the excitement, the energy, and the unforgettable experience of spending a day out with friends and family.
With just 3 weeks to go to one of the most iconic events in the sporting calendar, why not take a moment to ensure that you’re “race ready” and feeling your best? Randox Health’s comprehensive health checks are designed to help you stay energized, balanced, and ready to make the most of every moment of race day.
The Randox Grand National: A Day of Fun, Energy, and Excitement
The Randox Grand National is a day filled with excitement, cheers, and celebrations. Whether you’re attending Aintree or watching from home, the energy is infectious. But to truly make the most of the experience, it’s essential to feel your best. Just as the horses are carefully prepared for the race ahead, you too can set yourself up for success by taking control of your health.
Health Checks: The Ultimate Pre-Race Routine
At Randox Health, we believe that everyone deserves to feel their best. Our comprehensive health checks are designed to give you a complete picture of your well-being, so you can stay ahead of the game. Here’s what you can expect:
- Early Detection & Prevention:
Get ahead of potential health issues with advanced diagnostic screenings that catch problems before they become setbacks. - Personalised Insights:
Receive a personalized report on key health indicators—think of it as your personal performance analysis that guides your fitness and lifestyle choices. - Enhanced Performance & Recovery:
Understand how your body responds to stress, nutrition, and exercise. Whether you’re training for a race or just want to boost your everyday energy, knowing your body can help you fine-tune your routine.
How It Works: Simple, Efficient, and Effective
Our process is designed to be quick, efficient, and accessible—even with a busy schedule:
CHOOSE WELLNESS. Visit a Randox Health clinic or order a home test kit – it’s that simple
DON’T MISS A THING. Monitor thousands of health risks before symptoms show, giving you a clear snapshot of your health.
ADVICE THAT MATTERS. Get clear results, expert insights and guidance that makes a difference.
TAKE CONTROL. Make small lifestyle changes that can have a big impact
TRACK YOUR PROGRESS. Retest when you’re ready, see real improvements.
Get Race Day Ready with Randox Health
Race day is one of the most exciting days of the year, and we want you to feel your absolute best while enjoying every minute of it. Book your Randox Health check and get the insights you need to feel your best, recover after the excitement, and enjoy a day that’s full of fun, friends, and unforgettable moments.
To discover more visit: Randox Health | Health Checks & Blood Tests | Home Test Kits Available or get in touch- marketing@randox.com
Randox and Cormay Diagnostics Partner to Provide World-Leading EQA Programmes
Cormay Diagnostics and Randox Partner
Providing World-Leading Quality Assessment Programmes to Laboratories Worldwide
Cormay Diagnostics, a leader in diagnostic solutions, and Randox International Quality Assessment Scheme (RIQAS), a market leader in external quality assessment, have announced a strategic partnership to deliver world-class External Quality Assessment (EQA) programmes to laboratories across the globe.
The collaboration brings together the extensive expertise and experience of both companies to offer laboratories a comprehensive range of high-quality EQA schemes designed to enhance the quality and accuracy of laboratory testing worldwide. The partnership will allow Cormay Diagnostics to distribute and promote the RIQAS portfolio.
Supporting the shared mission of both Cormay Diagnostics and Randox to equip clinical laboratories of all sizes and budgets with cutting-edge technology and high-performance solutions. Helping all laboratories to meet regulatory requirements while boosting confidence in the accuracy of patient test results.
Cormay Diagnostics has over four decades of experience in manufacturing high-quality diagnostic reagents and providing laboratory solutions. The
company’s mission is to empower laboratories with the tools they need to ensure accurate, efficient, and reliable testing for healthcare professionals and patients worldwide.
Learn more: cormaydiagnostics.com
Founded in 1989, RIQAS is the worlds largest international External Quality Assessment Scheme with more than 76,000 laboratory participants spanning over 139 countries. With a product portfolio spanning 38 programmes, RIQAS offers participants a comprehensive yet cost effective solution to meeting regulatory requirements and increased confidence in test system accuracy.
Learn more: randox.com/riqas-external-quality-assessment
The Randox Grand National 2025 Trophy
The Randox Grand National 2025 Trophy
Randox is delighted to present the winner’s trophy for the Randox Grand National 2025. Expertly crafted by renowned Liverpudlian jewellery brand Boodles, this year’s trophy embodies the deep connection between Randox and the world’s most prestigious steeplechase, held annually at Aintree Racecourse. Inspired by Randox’s pioneering Biochip technology, the trophy’s striking design symbolises innovation, scientific advancement, and human endeavour. Subtle details within the craftsmanship also pay tribute to Aintree, seamlessly weaving elements of the iconic racecourse into its design.
Crafted with Purpose
The 2025 Randox Grand National Trophy is a masterpiece of design, seamlessly blending scientific innovation with the rich heritage of the world’s greatest steeplechase. The trophy prominently features a molecular structure and a DNA helix, represented by sixteen spheres and bars, mirroring the sixteen jumps of the Grand National course.
Encircling this intricate design is a stylised horseshoe, honouring the exceptional horses at the heart of this historic event and reflecting Randox’s deep-rooted passion for the sport. The trophy’s base, crafted from green malachite, is crowned with a Biochip-inspired design, inlaid with diamond discs. This element not only pays homage to Randox’s groundbreaking diagnostic technology but also evokes the tradition of incorporating precious gemstones into Grand National trophies throughout history.
Randox Founder and Managing Director, Dr. Peter FitzGerald, a passionate horseman himself, shared his thoughts on this year’s trophy:
“This year’s Randox Grand National Trophy, crafted by Boodles, is a stunning fusion of tradition and innovation. Its design, inspired by both Randox’s advancements in preventative healthcare and the rich legacy of the Grand National, is a fitting tribute to this world-renowned race. We are proud to collaborate with Boodles to celebrate excellence, heritage, and our shared commitment to pushing boundaries.”
Speaking on behalf of The Jockey Club, Dickon White, Regional Director for the West and Aintree Racecourse, stated:
“The Randox Grand National Trophy is a symbol of prestige, achievement, and history, and this year’s design by Boodles beautifully reflects these qualities. Their deep-rooted connection to both artistry and equestrian heritage makes them the perfect partner to create such an iconic piece. The trophy seamlessly blends Randox’s pioneering spirit with the enduring legacy of the Randox Grand National, resulting in a design that is both contemporary and timeless.”
A Return to Legacy
In recent years, Randox has designed the Grand National trophies in-house. However, for 2025, the honour has been entrusted once again to Boodles, a prestigious jeweller with a rich history of crafting Grand National trophies. This collaboration is driven by a shared passion for horse racing between Randox, Boodles, and The Jockey Club. Reflecting on this return to tradition, Michael Wainwright, Chairman of Boodles, shared his thoughts:
“Boodles is delighted to be partnering with Randox to design the 2025 Randox Grand National trophy. This collaboration is a wonderful opportunity to celebrate both the rich heritage of the Grand National and our longstanding connection to Aintree, with our company’s roots tracing back to 1798 in Liverpool, just a stone’s throw from the racecourse. We are honoured to play a part in commemorating this world-famous event with Randox.”
The Randox Grand National takes place 3rd – 5th April, 2025 at Aintree Racecourse.
Learn more here about the 3-day event here: The Grand National 2025 | 3-5 April 2025 | Aintree Racecourse
Randox renews Ulster National sponsorship at Downpatrick Racecourse
Randox renews Ulster National sponsorship at Downpatrick Racecourse
THE Ulster National, run at Downpatrick Racecourse since 1939, is one of the highlights of the racing year in Northern Ireland. It is therefore fitting that locally-based company Randox, whose racing portfolio has included the Aintree Grand National since 2017, has announced the renewal of their sponsorship of the Ulster National for the next five years, from 2025 until 2029. Randox will also sponsor 10 additional races at Downpatrick during each year.
This year’s Randox Ulster National will be held on Sunday, March 30th and is run over a distance of three miles and four furlongs, with a generous prize fund of €50,000.
Previous winners of the Ulster National include some well-known names: Caughoo won the Ulster National in 1945 and 1946 and went on to win the Aintree Grand National in 1947, ridden by jockey Eddie Dempsey and trained by Dublin-based Herbert McDowell. Laffy, owned by HRH Queen Elizabeth, The Queen Mother won the Ulster National in 1962, while more recently, Pineau de Re won the race in 2013, going on to claim the Aintree Grand National in 2014.
Randox is a global innovative healthcare diagnostics company, based in Crumlin, County Antrim and was founded in 1982 by Dr Peter FitzGerald, a medical scientist and keen horseman. The company’s sponsorship of racing includes the Randox Grand National at Aintree and title sponsorship of the three-day Randox Grand National Festival.
Randox sponsorship at Downpatrick began in 2020, with a five-year term having just come to an end. The renewal of this sponsorship for a further five years is a positive move for the racecourse and will certainly add to the excitement of the Ulster National for the next five years!
Be sure to put Sunday, March 30th into your diary!
Dr Peter FitzGerald CBE, Founder and Managing Director of Randox, said:
“This is an incredibly exciting time to be extending our partnership with Downpatrick Racecourse for the Randox Ulster National. Racing is a sport everyone can enjoy, from all different walks of life, and a partnership with Downpatrick offers us a fantastic opportunity to share our message of preventative health with a wide and engaged audience. The past five years, Randox has expanded into a strong and growing network of clinics across the UK & Ireland giving everyone the access they need to unlock their health. We look forward to the next five years of the Randox Ulster National.”
Ruth Morrison, Manager at Downpatrick Racecourse also said:
“I am thrilled that Randox has committed to extending their sponsorship of the Randox Ulster National at Downpatrick Racecourse for another five years, along with 10 additional races each season. The partnership over the past five years has been fantastic, and we are excited to continue building on that success.”
“Randox’s involvement in high-profile races such as the Grand National at Aintree highlights their dedication to our sport, we are proud to have them as a key partner in our racing community.”
“We would like to thank the FitzGerald Family and Team at Randox for their continued support and we look forward to the 2025 renewal of the Randox Ulster National on Sunday 30th March.”
Rapid Diagnosis of Bacterial Meningitis with Vivalytic
Rapid Diagnosis of Bacterial Meningitis with Vivalytic
Randox Laboratories, in collaboration with Bosch Healthcare Solutions (BHCS) is proud to announce the availability of the new Vivalytic Bacterial Meningitis panel on the Vivalytic platform. This highly advanced multiplex PCR test detects six of the most common bacterial pathogens responsible for meningitis, providing results in under an hour.
Meningitis is a critical medical emergency that requires rapid diagnosis to ensure timely and targeted treatment according to current guidelines (1). Over 2,5 million people are infected globally by meningitis each year, with half of these cases affecting children below the age of 5 (2). Furthermore, 20% of bacterial meningitis cases lead to permanent complications such as hearing loss, seizures or brain damage(3), if immediate treatment is not received, about 50% of cases will be fatal (4).
Enter Vivalytic
With a sample of only 200μl of cerebral spinal fluid (CSF), the Vivalytic Bacterial Meningitis Panel simplifies and accelerates the diagnostic process into 4 simple steps, delivering reliable results within 1 hour to support life-saving clinical decisions with the appropriate antibiotic treatment.
The panel detects key pathogens associated with bacterial meningitis:
| Detectable Pathogens | |
|---|---|
| Escherichia coli K1 | Neisseria meningitidis |
| Haemophilus influenzae | Streptococcus agalactiae |
| Listeria monocytogenes | Streptococcus pneumoniae |
The innovative all-in-one Vivalytic cartridge minimises the risk of contamination and reduces hands-on time for laboratory staff. This new panel aligns with our mission to improve patient outcomes and support healthcare providers with cutting-edge diagnostic solutions.
The Vivalytic Bacterial Meningitis panel is CE-marked and available to order. For further information on rapid diagnosis of bacterial meningitis with Vivalytic, please visit https://www.randox.com/vivalytic-bacterial-meningitis/ or contact your Randox representative.
References
- Pfister H.-W., Klein M. et al., Ambulant erworbene bakterielle Meningoenzephalitis im Erwachsenenalter, S2k-Leitlinie, 2023, in: Deutsche Gesellschaft für Neurologie (Ed.), Leitlinien für Diagnostik und Therapie in der Neurologie. https://dgn.org/leitlinie/ambulant-erworbene-bakterielle-meningoenzephalitis-im-erwachsenenalter
- GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2023 Aug;22(8):685-711
- GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. Erratum in: Lancet. 2020 Nov 14;396(10262):1562. https://pubmed.ncbi.nlm.nih.gov/33069326/ (retrieved on 12/17/2024)
- https://www.who.int/news-room/fact-sheets/detail/meningitis (retrieved on 12/17/2024)
Mpox Clade 1b Detected: How Rapid Testing with Vivalytic Can Aid in Containment
Mpox Clade 1b Detected: How Rapid Testing with Vivalytic Can Aid in Containment
Mpox, formerly known as Monkeypox, is a viral infection that has seen significant global attention due to recent outbreaks. As of August 2024, the UK has reported a total of 4,018 confirmed and highly probable mpox cases since May 2022 (1).
In October, the UK Health Security Agency (UKHSA) reported its first case of Clade 1b Mpox (2)—a more severe strain that has been spreading in the Democratic Republic of Congo (DRC) and other parts of Africa, prompting the World Health Organisation to declare it a public health emergency of international concern in August 2024 (3). This detection has led UKHSA to initiate contact tracing and monitor for potential further spread. Although the public risk is currently low, quick identification and containment remain vital for managing any risks associated with this High Consequence Infectious Disease (HCID).
According to a report on Mpox diagnostic testing published by the UKHSA, PCR testing remains the gold standard for Mpox detection, offering unmatched sensitivity and specificity essential for accurate diagnosis and effective containment (4). At Randox, with a strong commitment to public health and diagnostic innovation, we offer the Vivalytic MPXV Rapid Test to support healthcare professionals in identifying cases quickly and accurately, helping to strengthen containment efforts.
Understanding Mpox Clade 1b and Its Implications
Clade 1b of the mpox virus is part of the High Consequence Infectious Disease (HCID) category due to its higher transmission potential and more severe symptom profile compared to other strains. With a broad incubation period ranging from 5 days to 3 weeks (5), symptoms include:
• Skin rashes that progress to blisters or ulcers
• Fever, headaches, and muscle aches
• Swollen lymph nodes
• In severe cases, respiratory issues or widespread skin lesions
o Mpox infection is often self-limiting and usually lasts 2 to 4 weeks (5).
The transmission of mpox occurs through close contact with infectious lesions, bodily fluids, or contaminated materials. This can include skin-to-skin contact during sexual or intimate contact, as well as sharing items like bedding, towels, or clothing. Mpox infection is often self-limiting and usually lasts 2 to 4 weeks (5) and has a mortality rate estimated to be between 1% and 11% (6). Clade 1b’s recent spread outside of endemic regions, including cases in Germany, Sweden, and India (7) signals the need for proactive diagnostic and containment strategies.
Enter Vivalytic
The Vivalytic MPXV Rapid Test provides healthcare professionals with a comprehensive tool for detecting both Clade I (HCID, including Clade 1b) and Clade II of the Mpox Virus, as well as other Orthopoxvirus species. Its rapid and reliable performance is particularly valuable in high-stakes scenarios, where early detection can help prevent further spread. Key features include.
Features of the Vivalytic MPXV Panel
- Quick Results: Results in just 45 minutes allow for timely decision-making.
- Comprehensive Detection: This test identifies both Clade I (HCID, including Clade 1b) and Clade II of the Mpox Virus, as well as other Orthopoxvirus species such as cowpox and vaccinia virus.
- Minimal Sample Requirement: Only 300 µL needed, reducing sample handling and maintaining accuracy.
- Intuitive Workflow: The compact Vivalytic streamlines the entire molecular workflow through a 4-step process—scanning, inputting, adding the sample to the cartridge, and receiving results on the touchscreen display, all at the point of care.
| Detectable Pathogens | |
|---|---|
| Monkeypox Virus (Clade I, Clade II) | Non-variola Orthopoxvirus species (Coqpox Virus, Ectromelia Virus, Monkeypox Virus, Taterapox Virus, Vaccinia Virus) |
Supporting Public Health Responses with Randox
As part of our commitment to public health, Randox provides high-quality diagnostic tools designed to address infectious diseases like mpox. The Vivalytic MPXV Rapid Test supports rapid detection and strengthens the healthcare system’s ability to respond to emerging infectious threats. With the first UK case of Clade 1b now identified, rapid testing and response are essential components in the continued effort to protect public health.
Learn more about the Vivalytic, with one of the largest test menus on the market and how it can support your testing needs this winter here: Vivalytic | Point of Care | Randox Laboratories
Contact marketing@randox.com for more information
References
- UK (2024). Mpox (Mpox) outbreak: epidemiological overview, 8 August 2024. [online] GOV.UK. Available at: https://www.gov.uk/government/publications/Mpox-outbreak-epidemiological-overview/mpox-Mpox-outbreak-epidemiological-overview-8-august-2024.
- Thomas, R. (2024). First case of new potentially deadly mpox strain Clade 1b detected in UK. [online] The Independent. Available at: https://www.independent.co.uk/news/health/mpox-uk-clade-1b-monkeypox-b2638777.html [Accessed 6 Nov. 2024].
- World health Organisation (WHO). (2024). Mpox outbreak. [online] Available at: https://www.who.int/emergencies/situations/mpox-outbreak.
- UK Health Security Agency (UKHSA) (2024). Mpox (monkeypox): diagnostic testing. [online] GOV.UK. Available at: https://www.gov.uk/guidance/monkeypox-diagnostic-testing#sampling-for-diagnostic-testing.
- Guarner, J., del Rio, C. and Malani, P.N. (2022). Monkeypox in 2022—What Clinicians Need to Know. JAMA, [online] 328(2). doi:https://doi.org/10.1001/jama.2022.10802.
- CDC (2024). Mpox. [online] Mpox. Available at: https://www.cdc.gov/mpox/?CDC_AAref_Val=https://www.cdc.gov/poxvirus/mpox/travel/index.html [Accessed 6 Nov. 2024].
- Reed, J. (2024). New mpox strain spreads to household contacts in the UK. BBC News. [online] 4 Nov. Available at: https://www.bbc.co.uk/news/articles/cx27q0y6rl9o.
Fight Flu Season with Vivalytic
Fight Flu Season with Vivalytic!
As we enter the Winter 2024/25 flu season, healthcare providers and patients face the co-circulation of influenza, RSV, and SARS-CoV-2. This combination of respiratory pathogens presents unique challenges, particularly for vulnerable groups, and highlights the critical need for rapid, accurate diagnostics. Vaccination among frontline healthcare workers remains essential to reduce transmission, protect high-risk patients, and prevent staff shortages in healthcare facilities.
The Seasonal Threat of Respiratory Infections
Every year, influenza outbreaks affect millions globally, especially during winter. In England, 2023/2024 saw 2,776 flu-related deaths, highlighting the burden on healthcare systems. Vulnerable groups, including older adults, pregnant women, and those with chronic conditions, face heightened risks of severe outcomes like pneumonia or ICU admissions.
Pamela Rendi-Wagner, Director of the European Centre for Disease Prevention and Control, stressed that “vaccination is one of the most effective measures to protect vulnerable populations from severe disease, hospitalisation, and death.” Recent data shows significant variability in flu vaccination rates among older adults, ranging from 12% to 78% across Europe, with only two countries exceeding 75% coverage.
Vaccination remains the cornerstone of flu prevention for high-risk groups like the elderly, immunocompromised, and healthcare workers. However, diagnostic testing plays an equally vital role this flu season. Rapid and accurate testing prevents unnecessary hospitalisations, reduces severe outcomes in vulnerable populations, and ensures effective use of healthcare resources.
Enter Vivalytic
Accurate and rapid diagnosis is essential for effective treatment and control of respiratory infections, especially during flu season. By identifying the specific pathogen, healthcare providers can tailor treatment plans, combat anti-microbial resistance, reduce the spread within communities, and alleviate pressure on healthcare systems.
Enter Vivalytic; and with it the SARS, Flu A/B, and RSV Panel, offering an all-in-one solution for simultaneous testing of key respiratory pathogens. This panel ensures that healthcare professionals can diagnose and differentiate between influenza, RSV, and SARS-CoV-2 swiftly, providing crucial information to guide patient management.
Features of the Vivalytic SARS, Flu A/B and RSV Panel
- All-in-One Solution: Multi-pathogen testing with a single cartridge, eliminating the need for complex manual preparation.
- Rapid Results: With a turnaround time of just 53 minutes, the Vivalytic Flu panel enables swift decision-making, crucial in time-sensitive cases from a single nasopharyngeal or oropharyngeal swab sample.
- User-Friendly Design: An intuitive touchscreen interface requires minimal training, making it ideal for use in a variety of healthcare settings, including those with non-specialist operators.
| Detectable Pathogens |
|---|
| SARS-CoV-2 (E gene & N gene) |
| Influenza A and Influenza B |
| Human Respiratory Syncytial Virus |
Meeting the Challenges of the 2024/2025 Flu Season
As flu season progresses, the need for efficient and reliable diagnostics becomes ever more apparent. Fight Flu Season with Vivalytic, the SARS, Flu A/B, and RSV Panel is not only a valuable tool for diagnosing individual cases but also plays a critical role in protecting public health by enabling rapid response and management of outbreaks.
Learn more about the Vivalytic, with one of the largest test menus on the market and how it can support your testing needs this winter here: Vivalytic | Point of Care | Randox Laboratories
Contact marketing@randox.com for more information
Combatting AMR with Rapid UTI Diagnostics
Antimicrobial Resistance Awareness Week: Combatting AMR with Rapid UTI Diagnostics
Antimicrobial Resistance (AMR) poses one of the most critical health challenges of our time. Indeed, the World Health Organisation (WHO) has identified AMR as one of the top 10 global health threats (1). Furthermore, in the UK, AMR is recognised on the National Risk Register (2), reflecting the severity of the issue at both national and international levels. With AMR-related deaths reaching 4.95 million globally in 2019 (1), including 1.27 million directly attributed to resistant infections (1), urgent and coordinated action is required to preserve the efficacy of existing antimicrobials.
As part of Antimicrobial Resistance Awareness Week (18–24 November), we are focusing on the critical role of rapid diagnostics in combating AMR. Specifically, we are introducing the Randox Vivalytic UTI Rapid Test as a valuable tool in this global effort. By enabling faster and more accurate detection of infections, this innovative diagnostic technology supports the targeted use of antibiotics, thereby helping to reduce unnecessary prescriptions and mitigate the spread of resistance.
Understanding AMR: The Need for Effective Screening and Targeted Treatment
AMR develops when microorganisms such as bacteria, viruses, fungi, and parasites evolve to resist the effects of antimicrobial medicines. While this resistance occurs naturally, it is significantly accelerated by factors such as the overuse and misuse of antibiotics, poor infection control, and the slow pace of new antimicrobial drug development. Consequently, the implications of AMR extend far beyond infection treatment: surgeries, cancer therapies, and routine medical procedures also rely heavily on effective antimicrobials to prevent infections. Therefore, this underscores the pressing need to manage resistance effectively and proactively.
For instance, routine treatments for UTIs heavily depend on antibiotics. UTIs are among the most common bacterial infections, particularly affecting women, with over 50% experiencing a UTI at least once in their lives (3). However, with resistance levels increasing, it becomes crucial to avoid unnecessary antibiotic prescriptions. Additionally, when antibiotics are prescribed, they must be carefully targeted to maximise efficacy and minimise resistance development. In this context, rapid diagnostics play a pivotal role by enabling precise and timely identification of infections, which ensures that treatments are both effective and appropriate.
Introducing the Vivalytic UTI Rapid Test
The Randox Vivalytic UTI Rapid Test offers a cutting-edge solution for the efficient screening and diagnosis of UTIs. Unlike traditional culture methods—which, according to a recent study, take an average of 2.75 days to yield results (4)—the Vivalytic UTI Rapid Test is a cartridge-based PCR test specifically designed for in-clinic use, delivering results in just 2.5 hours. This rapid turnaround is transformative in the management of UTIs, where timely diagnosis is crucial to preventing the progression of infections. Moreover, it helps to minimise unnecessary antibiotic use by ensuring treatment is both prompt and precisely targeted, ultimately supporting the fight against antimicrobial resistance.
Key Features of the Vivalytic UTI Rapid Test:
- Comprehensive Detection: The Vivalytic UTI Rapid Test identifies 16 uropathogens, encompassing both gram-negative and gram-positive bacterial species, in just 150 minutes—significantly faster than traditional culture methods.
- AMR Gene Identification: This advanced test also detects 7 antimicrobial resistance genes, including those conferring resistance to methicillin (mecA) and vancomycin (vanA and vanB), as well as genes associated with trimethoprim resistance (dfrA1, dfrA5, dfrA12, dfrA17). This capability supports targeted treatment decisions and helps in combating antimicrobial resistance.
- Wide Application: Designed for versatility, the test is suitable for various healthcare settings, from GP practices to hospitals. It facilitates UTI diagnosis across diverse use cases, including catheter-associated UTIs and pre-surgical screenings for patients with conditions such as benign prostatic hyperplasia (BPH) or renal stones.
Additionally, a recent study demonstrated that the Vivalytic UTI Rapid Test achieved diagnostic accuracy exceeding 90% for 16 bacterial species, providing a reliable and efficient solution for rapid pathogen identification in UTI cases (4).
The Role of Rapid Diagnostics in Combating AMR
Rapid diagnostic tests, such as the Vivalytic UTI Rapid Test, play a critical role in addressing antimicrobial resistance (AMR) and improving patient care through the following:
- Reducing Misuse of Antibiotics: By rapidly identifying the specific bacteria responsible for the infection and detecting resistance genes, clinicians can prescribe antibiotics only when necessary. This targeted approach ensures that the most effective treatment is selected, helping to combat antibiotic misuse.
- Supporting Antimicrobial Stewardship: Point-of-care testing directly supports the goals outlined in the UK’s AMR 5-Year National Action Plan, which aims to reduce antibiotic consumption by 5% and ensure that 70% of antibiotics are sourced from safer, first-line options (5). Rapid tests enable optimised antibiotic usage, contributing to these national targets and the broader fight against AMR.
- Enhancing Patient Outcomes: Faster and more accurate diagnostics at the point of care enable timely and targeted treatment, reducing the risk of complications such as severe UTI-related kidney infections. Furthermore, a study on the Vivalytic UTI Rapid Test demonstrated that pathogen detection rates were slightly higher when tests were conducted immediately on-site, underscoring the importance of rapid diagnostics in delivering better patient outcomes (4).
AMR and the Future of Healthcare
The rise in AMR jeopardises the future of modern medicine. An estimated 10 million lives could be lost per year by 2050 (6), according to a review commissioned by the UK Prime Minister. Without effective diagnostics and treatments, procedures such as hip replacements, caesarean sections, and cancer therapies could become significantly more dangerous. This is due to the heightened risk of untreatable infections (1). Addressing this escalating threat requires innovation, education, and unwavering commitment.
AMR also imposes immense economic consequences. The World Bank projects that by 2050, AMR could add an extra US$1 trillion to global healthcare costs. It may also cause annual GDP losses ranging from US$1 trillion to US$3.4 trillion as early as 2030 (7). These economic burdens highlight the urgent need for global action.
Addressing AMR is crucial to achieving the Sustainable Development Goals (SDGs) outlined by the United Nations (UN). Progress in areas such as access to clean water, sustainable food production, and responsible antimicrobial use is vital in mitigating AMR. However, rising levels of AMR exacerbate challenges related to health, poverty reduction, food security, and economic growth (8). Coordinated efforts across multiple sectors are essential to tackle this complex issue effectively.
Randox is proud to lead the charge in the fight against antimicrobial resistance (AMR), equipping healthcare professionals with innovative tools such as the Vivalytic UTI Rapid Test. By enabling timely and accurate diagnoses, we contribute to preserving the efficacy of antimicrobials and safeguarding their availability for future generations.
This Antimicrobial Resistance Awareness Week, join us in highlighting the critical importance of AMR management and the transformative role of rapid diagnostics in creating a safer, healthier future for all.
Learn more about the urgency of AMR on the WHO website: Antimicrobial resistance.
For further details about the Vivalytic UTI Rapid Test, visit Vivalytic | UTI Rapid Test | Randox Laboratories or reach out to us at marketing@randox.com.
References
- World Health Organization (2023). Antimicrobial resistance. [online] World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.
- HM Government (2023). National Risk Register 2023 Edition. [online] Available at: https://assets.publishing.service.gov.uk/media/64ca1dfe19f5622669f3c1b1/2023_NATIONAL_RISK_REGISTER_NRR.pdf.
- Bono MJ, Reygaert WC. Urinary Tract Infection. Nih.gov. Published 2018. https://www.ncbi.nlm.nih.gov/books/NBK470195/
- Hartmann, J., Fritzenwanker, M., Imirzalioglu, C., Hain, T., Arneth, B.M., and Wagenlehner, F.M.E., 2024. Point-of-care Testing in Complicated Urinary Tract Infection: Evaluation of the Vivalytic One Urinary Tract Infection Analyser for Detecting Uropathogenic Bacteria and Antimicrobial Resistance in Urine Samples of Urological Patients in a Point-of-care Setting. European Urology Focus. Available at: https://doi.org/10.1016/j.euf.2024.09.018
- Department of Health and Social Care (2024). UK 5-year action plan for antimicrobial resistance 2024 to 2029. [online] GOV.UK. Available at: https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2024-to-2029.
- O’Neill, J. (2016). Tackling Drug-resistant Infections Globally: Final Report and Recommendations. Archives of Pharmacy Practice, 7(3), p.110. doi:https://doi.org/10.4103/2045-080x.186181.
- World Bank (2017). Drug-Resistant Infections: A Threat to Our Economic Future. [online] World Bank. Available at: https://www.worldbank.org/en/topic/health/publication/drug-resistant-infections-a-threat-to-our-economic-future.
- World Health Organization (WHO) (2021). Antimicrobial resistance and the United Nations sustainable development cooperation framework: guidance for United Nations country teams. [online] www.who.int. Available at: https://www.who.int/publications/i/item/9789240036024.
Acusera 24Ā·7 and Data Innovations – Automated QC Data Upload
Automated QC Data Upload to Acusera 24·7
Now Available via Instrument Manager™ from Data Innovations
Randox Laboratories in conjunction with Data Innovations are pleased to announce the launch of a new driver that enables seamless, automated QC data upload via API from any instrument connected to Instrument Manager (IM) directly into Acusera 24.7. This new feature eliminates the need for manual data entry, reduces transcription errors and improves laboratory efficiency.
What you need to know
Uni-Directional License – Anyone wishing to avail of automated QC data upload to Acusera 24.7 will need a uni-directional license for Instrument Manager. A new license can be requested directly from a Data Innovations representative, or an existing license previously used for an analyser may be re-purposed.
Driver Download – Once a license has been secured, you will be required to download the Acusera 24.7 Driver from the MY DI Community website – https://datainnovations.my.site.com/s/drivers. To locate the driver simply select Randox from the Manufacturer drop down menu and then select Acusera 24.7 from the list of available drivers.
Configuration – Once the driver has been downloaded, you will receive help files that document the process to be followed. The same steps are to be followed as with connecting any instrument or analyser to Instrument Manager.
Once the driver has been successfully set up, Instrument Manager will automatically send QC data to Acusera 24.7, removing the need for manual data entry.
Key Considerations
- You must have have an Acusera 24.7 license and configured your Acusera 24.7 account before connecting to Instrument manager.
This new capability allows laboratories to optimise workflows, reduce errors, and streamline QC data management.
About Data Innovations
Data Innovations is a global software company that is passionate about excellence in patient care. Through innovative solutions and world-class service, they enable enterprise management of hospitals and independent laboratories. Founded in 1989 with headquarters in Vermont, Data Innovations serves more than 6,000 hospitals and laboratories in 80+ countries.
What is Instrument Manager?
Laboratory Information Management Systems (LIMS) by Data Innovations LLC
Instrument Manager™ (IM) is a truly vendor-neutral middleware platform that allows for the connection of any clinical lab instrument to any Lab Information System (LIS), with a library of over 1,000 instrument drivers. IM offers a suite of lab enablement solutions spanning productivity, quality, analytics, performance and reliability.
Labs using IM auto verification with time-saving workflows are able to achieve quicker turnaround times and increased productivity. IM quality assurance programs ensure that all connected instruments deliver the most accurate possible test results.